The increasing rates of kidney cancer incidence, reported in many populations globally, have been attributed both to increasing exposures to environmental risk factors, as well as increasing levels of incidental diagnosis due to widespread use of imaging. To better understand these trends, we examine long-term cancer registry data worldwide, focusing on the roles of birth cohort and calendar period, proxies for changes in risk factor prevalence and detection practice respectively. We used an augmented version of the Cancer Incidence in Five Continents series to analyze kidney cancer incidence rates 1978-2007 in 16 geographically representative populations worldwide by sex for ages 30-74, using age-period-cohort (APC) analysis. The full APC model provided the best fit to the data in most studied populations. While kidney cancer incidence rates have been increasing in successive generations born from the early twentieth century in most countries, equivalent period-specific rises were observed from the late-1970s, although these have subsequently stabilized in certain European countries (the Czech Republic, Lithuania, Finland, Spain) as well as Japan from the mid-1990s, and from the mid-2000s, in Colombia, Costa Rica and Australia. Our results indicate that the effects of both birth cohort and calendar period contribute to the international kidney cancer incidence trends. While cohort-specific increases may partly reflect the rising trends in obesity prevalence and the need for more effective primary prevention policies, the attenuations in period-specific increases (observed in 8 of the 16 populations) highlight a possible change in imaging practices that could lead to mitigation of overdiagnosis and overtreatment.
With over 337,000 new cases estimated globally in 2012, kidney cancer is the 9th most common cancer in men and 14th in women. Incidence rates in men vary at least 15-fold, from <1 per 100,000 (age-standardized rates, world standard) in low-risk countries on the African continent through to over 15 in several Northern and Eastern European countries and in the US; similar patterns, albeit with half the magnitude seen in men, are observed in women. 1 Following the introduction and widespread utilization of imaging techniques in 1980s, in particular ultrasound and computed tomography, kidney cancer has become an increasingly important neoplasm in highly developed countries, [2] [3] [4] [5] where it has been estimated that up to 70% of the new cases are discovered incidentally. 3, 6 Whereas the incidence rates have been increasing globally, the recent mortality trends are stable in many countries, with significant declines reported from Western and Northern Europe, US and Australia. 5 In term of etiology, there is a hereditary component and an expanding knowledge of genetic susceptibility; several modifiable risk factors are well documented, notably obesityresponsible for up to 28% of cases in North America 7 -as well as smoking and hypertension. [8] [9] [10] Morphologically, over 90% of kidney cancers are renal cell carcinomas, with clear cell (70%), papillary (10-15%) and chromophobe (5%) carcinoma the main histological types. 11 Enhanced molecular characterization has led to a better understanding of the complexity of the disease, with six new codes approved by the International Agency for Research on Cancer (IARC)/World Health Organization (WHO) Committee for International Classification of Diseases for Oncology (ICD-O) included in the new WHO Classification of the Tumours of the Urinary System and Male Genital Organs 12 ; yet many research questions still remain difficult to answer: including specific factors explaining geographical, ethnic and sex differences, the biological pathways underlying the association with known risk factors; and the critical data required to understand genomic and epigenetic changes. possible explanatory factors. 5 Using incidence data covering years 1978-2007, the aim of this study is to elucidate the reasons for the increasing kidney cancer incidence by investigating the role of birth cohort (a surrogate for increased exposures to environmental risk factors, such as obesity, operating in successive generations) and period-specific effects (commonly a proxy for changes in diagnostic practices or disease classification).
Material and Methods
The number of new cases of kidney cancer was obtained by site (ICD-10 code C64), year of diagnosis, sex and 5-year age Group (0-4, 5-9,. . ., 80-84, 851) from regional or national population-based cancer registries in 38 countries for the maximal period 1953-2011, extracted from Cancer Incidence in Five Continents (CI5) Volumes I to X.
14 The inclusion requirement was at least 15 consecutive years of data and compilation in the tenth volume of the CI5 series, a criterion indicative of each registry's data quality over time, given that the editorial process involves a detailed assessment of the comparability, completeness and validity of the incidence data. To improve on the timeliness of the information, the dataset was supplemented with data up to 2011 published by the corresponding cancer registries, accessible online or via a special request to the cancer registry. Thus the final datasets covered the years 1988-2007 as a minimum (China, Italy, Spain) and 1978-2011 as a maximum (Denmark, Finland, US); corresponding population data were obtained from the same sources as the incidence data. We restricted presentation to 16 populations on the basis of geographical representation and whether the observed rates could be meaningfully visually interpreted. Of the 15 countries thus represented in our study, we obtained national data for 7 countries. For the remaining countries, regional registry data were aggregated to obtain a proxy of the national incidence; U.S. trends for Blacks and Whites separately. The total number of new cases of kidney cancer included in the age-restricted analysis was 336,072, equivalent to 73% of all cases irrespective of age. We present annual trends in age-truncated kidney cancer incidence rates (ages 30-74, world standard) by sex for each population. 15 We analyzed country and sex-specific kidney cancer incidence trends by 5-year age group (ages and calendar period, with synthetic and overlapping birth cohorts obtained on subtracting the midpoints of 5-year age groups (30-34, 35-39,. . ., 70-74) from the corresponding 5-year periods. The observed trends in incidence rates versus birth cohort and period by age were graphically presented using a semilog plot. In terms of modelling, we fitted age-period-cohort (APC) model, 16, 17 assuming the incidence rates were constant within the 5-year age classes and 5-year periods of diagnosis p and that the number of new cases followed a Poisson random variable with the logarithm of the person-years at risk specified as an offset:
where k refers to the rate, while a a , b p and c c are respective functions of age a, period p and birth cohort c. The nonidentifiability inherent in APC analyses-knowledge of the values of any two of age, period and cohort implies knowledge of the third, making one of the factors redundant-is commonly managed by constraining the linear component of either the period or the cohort effect to have zero slope, thereby attributing the linear changes in incidence to cohort or period-related factors respectively. As both cohort and period influences have been implicated in kidney cancer incidence trends, we present both scenarios as Supporting Information materials. The model analysis and presentation was performed using apc.fit in R.
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Results Figure 1 displays the trends in truncated age-standardized incidence rates of kidney cancer in males and females by population within world region. In most of the analyzed populations, the full APC model provided a reasonable fit to the data, the exceptions being Belarus, Japan and UK males, where no model fitted the data (Supporting Information Table 1 ). Figure 2 presents the observed age-specific rates vs. cohort and period, while the equivalent model-based incidence rate ratios obtained from the full APC models are graphically depicted in Supporting Information Figure 1 , based on an allocation of drift to period and cohort, respectively. In Europe, the steepest increases in kidney cancer incidence rates were observed in Lithuania and Belarus (over 8-fold increases in both sexes between 1980 and 2000), possibly with some attenuation in rates on the period scale in Lithuania since 2000. Moderately increasing trends were observed What's new? The increasing rates of kidney cancer incidence have been attributed to increasing exposure to environmental risk factors and increasing levels of incidental diagnosis. Here, the authors find that the effects of birth cohort (a proxy for changes in risk factor prevalence) and calendar period (a proxy for changes in detection practice) both contribute to the international kidney cancer incidence trends. Furthermore, while cohort-specific increases may partly reflect the rising trends in obesity and the need for more effective primary prevention policies, attenuations in period-specific increases in high-incidence countries highlight a possible change in imaging practices with potential overdiagnosis mitigation. 
Cancer Epidemiology
Znaor et al.
in France, Italy, Spain and the UK, with the increase most prominent in Spain, followed by stabilization on the period scale, also around 2000. In the Czech Republic, a doubling of incidence rates was observed in both sexes between 1985 and 1995, after which incidence rates stabilized or declined, particularly in women. Modest increases in incidence rates were observed in Denmark and Finland, cohort effects appeared dominant among Danish women, with generational decreases observed in successive cohorts born from the mid-1950s. Period effects were more evident in Finland, with declines observed in both sexes from 1990s ( Figs. 1 and 2 , Supporting Information Fig. 1) .
In Australia, incidence rates increased by about two thirds between 1980s and 2000 in both sexes, with an indication of a stabilization of trends thereafter (Figs. 1 and 2 ). In the US, the full APC model provided the best fit for Whites, and the age-cohort model for Blacks (Supporting Information Table  1 ). Among both ethnicities (except black women), incidence rates rose moderately in successive cohorts, then steeply for cohorts born in 1960s and thereafter. No indication of period-specific stabilization was noted.
Of the two Asian populations analyzed, steep and continuous increases in incidence rates were observed on both birth cohort and period scales in China (3-fold increases from 1990s to mid-2000s), while in Japan the increases stabilized according to calendar period around the mid-1990s in both sexes ( Figs. 1 and 2, Supporting Information Fig. 1 ). In the Latin American countries analyzed, risk appeared to increase according to successive birth cohorts and periods, and more prominently among men, with the age-drift model providing the best fit (Supporting Information Table 1 ). Period effects were also observed with close to twofold increases in both sexes from 1980s followed by stabilizing trends since 2000 in both sexes in Costa Rica and in Colombian men (Figs. 1 and  2, Supporting Information Fig. 1 ).
Discussion
Our study confirms the reports of increasing kidney cancer incidence trends globally, 5, 19 with persisting increments in cohort-specific risk in many countries. We did however observe a stabilization of incidence in several populations, from the mid-1990s in Eastern Europe (Czech Republic), Northern Europe (Finland and Lithuania) and Japan, and 5-10 years later in Southern Europe (Spain), South America (Colombia and Costa Rica), as well as Australia. The full APC model tended to provide the best fit in most populations and in both sexes, confirming the importance of all three components in kidney cancer incidence trends.
While the environmental risk factors driving the rising generational risks in kidney cancer incidence have been discussed elsewhere [8] [9] [10] -including the rising prevalence of obesity as an increasingly important determinant globally 7 -the period effects observed in several populations are less frequently explored. [20] [21] [22] To our knowledge, this is the first study reporting the stabilization of period-specific incidence trends across a number of high-incidence countries. The presence of overdiagnosis via an increased detection of incidental tumors has been repeatedly implicated in the steadily increasing incidence rates of kidney cancer, particularly in Northern America and Europe. 2, 4, 23, 24 Our results suggest that more conservative diagnostic practices have been in operation in recent years in Japan, Australia and certain countries within Latin America and Europe. An increasingly conservative approach to imaging has been documented in the Czech Republic, the country with highest incidence of kidney cancer worldwide, beginning in the mid-1990s 20 ; we have yet to identify similar patterns in other countries.
In the United States, a doubling of the kidney cancer incidence rates from 1975 to 2005 and the low and stable corresponding mortality rates have been cited as an example of overdiagnosis of the disease by Welch and Black. 4 Our results are consistent with the results of an APC analysis of the U.S. SEER data 1973-2008 by Tyson et al., 21 where uniform period-related increases were observed alongside marked increases in risk among generations born since the early1960s. Further evidence of the importance of both period and cohort effects in the US is provided by a recent study demonstrating rising rates of localized renal cell carcinoma incidence and mortality. 25 Although our results do not provide an indication of period-specific stabilizations in the US, the recently-reported decrease in use of diagnostic imaging in the last decade (2000-2009) will possibly reflect on future trends. 26 While successes in mitigating overdiagnosis may be obscured by overall increases in the incidence rates of kidney cancer, the study of cervical cancer trends provides an example where period-specific screening-related declines can deflect overall rates downwards despite concurrent generational increases in risk linked to changing sexual behavior and high-risk HPV persistence. 27, 28 The problem of overdiagnosis, and medical overuse in general has come into focus only recently 29, 30 ; overdiagnosis in cancer was specifically addressed at a meeting convened by the U.S. National Cancer Institute (NCI) in 2012 31 on the back of a review by Welch and Black in 2010. 4 Alterations in classification or coding are commonly implicated artifacts in explaining fixed or delayed periodspecific changes in trends, affecting all ages. Examples include the reclassification of low-grade papillary carcinoma of the bladder to papilloma and changes of behavior code 3 (malignant) to 1 (uncertain whether benign or malignant) of ovarian cystadenomas of borderline malignancy. 32, 33 Given the challenges in developing diagnostic tests that can differentiate indolent and aggressive forms of common neoplasms, an initial recommendation from the NCI meeting on overdiagnosis of cancer was to change terminology and adopt the term "IDLE" (indolent lesion of the epithelium) instead of "cancer" for lesions that would likely not progress. 31 A recent example from kidney cancer morphology is the reclassification of the "multilocular cystic renal cell carcinoma", which accounts for approximately 4% of all clear cell renal carcinomas, to "multilocular cystic renal neoplasm of low malignant potential". The IARC/WHO Committee for ICD-O approved the new code, 8316/1, published in the WHO Classification of Tumours of the Urinary System and Male Genital Organs. While morphological profiling is increasing in precision, and the prospects of identifying other renal cell carcinoma types of low malignant potential, such as clear cell papillary renal cell carcinoma for future reclassification, 12, 34, 35 reliable prognostic markers that could help distinguish between indolent and aggressive forms of kidney cancer are still lacking. The predominance of benign or indolent pathologies and very low risk of metastatic progression has led to the paradigm shift of treatment of small renal masses, with partial nephrectomy, thermal ablation and active surveillance as the approaches preferred to radical nephrectomy. [36] [37] [38] There are a number of limitations to our study. The non-identifiability problem inherent in APC analyses necessitated the presenting of model parameters on a limited number of datasets (with sufficient data span) using two scenarios whereby the linear trend (drift) was allocated either to period or cohort. In some populations such analyses were non-informative, including Colombia, Costa Rica and France, where the age-drift model provided the best fit, indicating no significant (non-linear) period or cohort effects after age adjustment. In addition, the lack of stage information meant that insight into the impact of overdiagnosis of kidney cancer incidence at the population level was limited.
The present kidney cancer incidence trends represent a complex interplay of age, calendar period and birth cohort effects. The role of primary prevention is well-establishedcurbing the prevalence of obesity and smoking, is central to attenuating the observed generational increases worldwide [8] [9] [10] -yet the concept of implementing "overdiagnosis prevention" has only been recently introduced. 39 The discussion has largely been confined to the highest income countries, however, optimizing the distribution and reducing overspending already modest resources is a challenge also faced by low-and middle-income countries.
In conclusion, even if the number of kidney cancer patients continues to rise year-on-year due to aging populations and an increasing prevalence of factors linked to westernized lifestyles (in countries in transition), a stabilization of period-specific risk has been observed in some of the highest incidence populations. Lowering the volume of uncritical use of medical imaging and increasing the accuracy in the characterization of some specific morphologies (as indolent lesions) could lead to a further attenuation of the increasing incidence rates worldwide and a reduction of overdiagnosis and overtreatment.
